INNATE PHARMA SA (IPHA) News
Filter IPHA News Items
IPHA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IPHA News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest IPHA News From Around the Web
Below are the latest news stories about INNATE PHARMA SA that investors may wish to consider to help them evaluate IPHA as an investment opportunity.
Innate Pharma Announces Transformative Strategy to Accelerate GrowthMARSEILLE, France, January 10, 2025--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced its updated strategy for company growth. This comprehensive plan is anchored in three key pillars designed to drive sustainable growth, foster innovation, and deliver transformative therapies to patients worldwide. |
Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceMARSEILLE, France, December 20, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that its management will present and host 1x1 meetings at the 43rd Annual J.P. Morgan Healthcare Conference being held on January 13-16, 2025 in San Francisco, CA. |
3 Promising Penny Stocks With Market Caps Under US$300MAs global markets experience a mixed performance, with major U.S. indices reaching record highs while others face declines, investors continue to navigate through a complex economic landscape. Amidst this backdrop, penny stocks remain an intriguing option for those looking to explore smaller or less-established companies that may offer value and growth potential. Despite being considered an outdated term by some, penny stocks highlight opportunities in firms with strong financials and the... |
Innate Pharma SA Reveals Promising Lacutamab Trial ResultsInnate Pharma SA (FR:IPH) has released an update. Innate Pharma SA has unveiled promising data from its TELLOMAK Phase 2 study, highlighting the potential of lacutamab to improve the quality of life for patients with cutaneous T-cell lymphoma. The study shows significant alleviation of symptoms such as severe itching and skin infections, offering hope for those with limited treatment options. For further insights into FR:IPH stock, check out TipRanks’ Stock Analysis page. |
Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell LymphomaMARSEILLE, France, December 09, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced new data highlighting the quality-of-life improvements observed in patients with cutaneous T-cell lymphoma (CTCL) treated with lacutamab in the TELLOMAK Phase 2 clinical study. These data were presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, California. |
Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular LymphomaMARSEILLE, France & DIAMOND BAR, Calif., December 06, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), together with the Institute for Follicular Lymphoma (IFLI) today announced that they have entered into an agreement to clinically study the potential of IPH6501, Innate's anti-CD20 ANKET® in follicular lymphoma (FL). |
Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024MARSEILLE, France, December 03, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that abstracts related to lacutamab health-related quality of life and translational data from the TELLOMAK trial and SAR443579, Sanofi-partnered ANKET® asset, have been selected for the American Society of hematology (ASH) Annual Meeting. |
Innate Pharma Releases Its 2025 Financial CalendarMARSEILLE, France, November 20, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today released its 2025 financial calendar: |
Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501MARSEILLE, France, November 19, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced the publication in Science Immunology of preclinical data demonstrating the potential of IPH6501, Innate’s proprietary NK cell engager including an IL-2v and targeting CD20 from the ANKET® platform. IPH6501 is currently evaluated in a Phase 1/2 clinical trial in B-cell non-Hodgkin lymphoma (B-NHL) (NCT06088654). |
Discover 3 Promising Penny Stocks With Over US$90M Market CapGlobal markets have been experiencing significant movements, with U.S. stocks rallying to record highs following a "red sweep" in the elections, which has raised expectations for growth and tax reforms. In this context of shifting economic policies and market optimism, investors are increasingly looking at under-the-radar opportunities that can offer potential growth without excessive risk. Penny stocks, though an older term, remain relevant as they often represent smaller or newer companies... |